Chemokine receptor expression on integrin-mediated stellate projections of prostate cancer cells in 3D culture

Cytokine

Volumn 64, Issue 1, 2013, Pages 122-130

  Kiss, Debra L ^a   Windus, Louisa C E ^a   Avery, Vicky M ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

3D culture; Chemokine receptor; CXCR4; CXCR7; Prostate cancer

Indexed keywords

BETA1 INTEGRIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; INTEGRIN; LAMININ; LAMININ BETA; MATRIGEL; STROMELYSIN 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORPHOLOGY; CARCINOGENESIS; CELL INTERACTION; CELL STRAIN DU145; CELL STRAIN LNCAP; CELL STRAIN PC3; CELL STRUCTURE; CONTROLLED STUDY; CULTURE TECHNIQUE; EXTRACELLULAR MATRIX; PANCREATIC STELLATE CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; THREE DIMENSIONAL CULTURE; TUMOR INVASION; TWO DIMENSIONAL CULTURE;

2-DIMENSIONAL; 2D; 3-DIMENSIONAL; 3D; 3D CULTURE; CHEMOKINE RECEPTOR; CXC CHEMOKINE RECEPTOR 4; CXC CHEMOKINE RECEPTOR 7; CXCR4; CXCR7; ECM; EMT; EPITHELIAL-TO-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; MATRIX METALLOPROTEINASE 11; MMP-11; PCA; PROSTATE CANCER; SDF-1Α; STROMAL DERIVED FACTOR-1 ALPHA;

ANTIGENS, CD29; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CHEMOKINE CXCL12; EXTRACELLULAR MATRIX; HUMANS; LAMININ; MALE; MATRIX METALLOPROTEINASE 11; PROSTATIC NEOPLASMS; RECEPTORS, CXCR; RECEPTORS, CXCR4;

EID: 84883554810     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.07.012     Document Type: Article

References (39)

1. Wang J., Shiozawa Y., Wang J., Wang Y., Jung Y., Pienta K., et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1α in prostate cancer. J Biol Chem 2008, 283(7):4283-4294.
2. Burns J., Summers B., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion and tumor development. J Exp Med 2006, 203(9):2201-2213.
3. Maio Z., Luker K., Summers B., Berahovich R., Bhojani M., Rehemtulla A., et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Nat Acad Sci USA 2007, 104(40):15735-15740.
4. Mochizuki H., Matsubara A., Teishima J., Mutaguchi K., Yasumoto H., Dahiya R., et al. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 2004, 320(3):656-663.
5. Wang Y., Mikhailova M., Bose S., Pan C., DeVere White R., Ghost P. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008, 27(56):7106-7117.
6. Hou K., Hao M., Bo J., Wang J. CXCR7 in tumorigenesis and progression. Chin J Cancer 2010, 29(4):456-459.
7. Duda D., Kozin S., Kirkpatrick N., Xu L., Fukumara D., Jain R. CXCL12 (SDF1α) - CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anti-cancer therapeutics. Clin Cancer Res 2011, 17(8):2074-2080.
8. Kozin S., Kamoun W., Huang Y., Dawson M., Jain R., Duda D. Recruitment of myeloid but not endothelial precursor cells facilitates tumor re-growth after local irradiation. Cancer Res 2010, 70(14):5679-5685.
9. Kioi M., Vogel H., Schultz G., Hoffman R., Harsh G., Brown J. Inhibition of vasculogenesis but not angiogenesis, prevenst the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120(3):694-705.
10. Redjal N., Chan J., Segal R., Kung A. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 2006, 12(22):6765-6771.
11. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008, 25(4):345-356.
12. Vandercappellen J.Van., Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008, 267(2):226-244.
13. Wang J., Loberg R., Taichman R. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006, 25(4):573-587.
14. Décaillot F., Kazmi M., Lin Y., Ray-Saha S., Sakmar T., Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 2011, 286(37):32188-32197.
15. Sierro F., Biben C., Martinez-Munoz L., Mellado M., Ransohoff R., Li M., et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Nat Acad Sci USA 2007, 104(37):14759-17764.
16. Luker K., Gupta M., Steele J., Foerster B., Luker G. Imaging ligand-dependent activation of CXCR7. Neoplasia 2009, 11(10):1022-1035.
17. Singh R., Lokeshwar B. The IL-8 regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 2011, 71(9):3268-3277.
18. Boudot A., Kerdivel G., Habauzit D., Eeckhoute J., Le Dily F., Flouriot G., et al. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS ONE 2011, 6(6):e20898.
19. Kalatskaya I., Berchiche Y., Gravel S., Limberg B., Rosenbaum J., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009, 75(5):1240-1247.
20. Gravel S., Malouf C., Boulais P., Berchiche Y., Oishi S., Fujii N., et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem 2010, 285(49):37939-37943.
21. Fischbach C., Kong H., Hslong S., Evangelista M., Yuen W., Mooney D. Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. PNAS 2009, 106(2):399-404.
22. Nyga A., Cheema U., Lozidou M. 3D tumor models: Novel in vitro approaches to cancer studies. J Cell Commun Signal 2011, 5(3):239-248.
23. Zschenker O., Streichert T., Hehlqans S., Cordes N. Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PLoS ONE 2012, 7(4):e34279.
24. Clarke N., Hart C., Brown M. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009, 11(1):57-67.
25. Windus L.C., Kiss D.L., Glover T., Avery V.M. In vivo biomarker expression patterns are preserved in 3D cultures of prostate cancer. Exp Cell Res 2012, 318(19):2507-2519.
26. Busillo J., Benovic J. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007, 1768(4):952-963.
27. Ray P., Mihalko L., Coggins N., Moudgil P., Ehrlich A., Luker K., et al. Carboxy-terminus of CXCR7 regulates receptor localization and function. Int J Biochem Cell Biol 2012, 44:669-678.
28. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113(24):6085-6093.
29. Harma V., Virtanen J, Makela R, Happonen A, Mpindi J, Knuuttila M, et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5(5):e10431.
30. Belkin A., Stepp M. Integrins as receptors for laminins. Microsc Res Tech 2000, 51(3):280-301.
31. Castronovo V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 1993, 13(1):1-30.
32. Andarawewa K., Boulay A., Masson R., Mathelin C., Tomasetto C., Chenard M., et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003, 63(18):5844-5849.
33. Basset P., Okada A., Chenard M., Kannan R., Stoll I., Anglard P., et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol: J Int Soc Matrix Biol 1997, 15(8-9):535-541.
34. Cheng C., Yu J., Wang H., Huang C., Shieh J., Fu Y., et al. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Int J Clin Chem (Clinica Chimica Acta) 2010, 411(3-4):234-241.
35. Masson R., Lefebvre O., Noel A., Fahime M., Chenard M.P., Wendling C., et al. In vivo evidence that the stromeolysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998, 140(6):1535-1541.
36. Noel A., Boulay A., Kebers F., Kannan R., Hajitou A., Calberg-Bacq C., et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000, 19(12):1605-1612.
37. Li Y., Pan Y., Wei Y., Cheng X., Zhou B., Tan M., et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6(5):459-469.
38. Chinni S., Yamamoto H., Dong Z., Sabbota A., Bonfil R., Cher M. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008, 6(3):446-457.
39. Singh S., Singh U., Grizzle W., Lillard J.J. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest: J Tech Meth Pathol 2004, 84(12):1666-1676.